SecBot SecBot

ANNX

Annexon, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001528115 Biotech & Drug Discovery
$3.75 −0.06 (−1.57%)
Oct 23 4:00 PM ET · prev $3.81
Market cap
$722.3M
Small cap
Consensus
Buy
82% Buy or better · 17 analysts
Median target
🔒 Subscribers only
1 year
+16.8%
from $3.21 · Oct 24
30 days
−1.3%
from $3.80
52-week range
$2.68–6.96
−46% from high · low Nov 13
Avg volume 20D
3.83M
shares / day
Short interest
32.01M
≈16.9% of shares · −2.6%
Days to cover
8.9
at average volume
Insider net
+$3.2M
3 buyers · 5 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
11
analyzed by SecBot
SecBot read BULLISH 6 reports · 90 days
Balance 0 bearish · 4 bullish · 1 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 4/6 ·Next Earnings date, Nov 16, 2026
Strongest BULLISH Annexon announced early positive data from the FORWARD open-label study of tanruprubart in Guillain-Barré…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    3 insiders bought $3.6M at an average $5.37. 5 insiders sold $313.4K. Price is 30% below their cost.

  • InstitutionsMIXED

    Q2 2026: 26 added (0 new), 20 trimmed or exited.

  • AnalystsBULLISH

    14 of 17 rate it Buy or better.

  • Short sellersSTEADY

    Short interest −2.6% to 32.01M shares. 8.9 days to cover, ≈16.9% of shares.

  • TrendDOWNTREND

    14% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
FMR LLCADD19,518,496$111.5M
STATE STREET CORPADD9,824,321$56.1M
Woodline Partners LPDOUBLED6,925,067$39.5M
GOLDMAN SACHS GROUP INCDOUBLED5,825,579$33.3M
BALYASNY ASSET MANAGEMENT L.P.TRIM2,830,976$16.2M
Nuveen, LLCTRIM2,765,080$15.8M
VANGUARD PORTFOLIO MANAGEMENT LLCADD2,246,800$12.8M
DIMENSIONAL FUND ADVISORS LPADD1,497,756$8.6M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

17 analysts
Buy 82% rate it Buy or better
Strong Buy4Buy10Hold3Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Oct 19, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Sep 30, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Sep 1, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Aug 13, 2026Citizens
UPGRADE
UPGRADEMarket Perform
Jul 21, 2026Citizens
INITIATE
INITIATEMarket Underperform
Jul 15, 2026Needham
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$3.6M
bought · 3 insiders
$313.4K
sold · 5 insiders
−30.1%
vs their $5.37 cost
DateInsiderTypeValue
Sep 24, 2026
Love Douglas
PRESIDENT AND CEO
BUY$99.8K
Aug 10, 2026
Blumenkranz Mark S.
Director
AWARD175,000 sh
Jun 11, 2026
Yednock Ted
EVP & CHIEF INNOVATION OFFICER
EXERCISE$56.7K
Jun 11, 2026
Carson William H.
Director
AWARD65,000 sh
Jun 11, 2026
Cockroft Bettina M.
Director
AWARD65,000 sh
Jun 11, 2026
JONES WILLIAM A JR
Director
AWARD65,000 sh
Jun 11, 2026
Choi Jung
Director
AWARD65,000 sh
Jun 11, 2026
Satter Muneer A
Director
AWARD65,000 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only

Short side

FINRA· Sep 30, 2026
32,009,914
shares short
-2.6%
vs prior settlement
8.9
days to cover
≈16.9%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 16, 2026 Other
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutica
Sep 24, 2026 Insider
Love Douglas bought 26,065 shares
PRESIDENT AND CEO @ $3.83 ($99.8K)
Aug 13, 2026 SEC
Citizens upgrades ANNX to Market Perform from Market Underperform — No PT Set
ANALYST-UPGRADE — Impact 4/10
Aug 12, 2026 SEC
Annexon reported Q2 2026 EPS of -$0.28, slightly wider than the prior year's -$0.34 loss, but the focus is on pipeline…
PRESS-RELEASE — Impact 6/10
Aug 12, 2026 SEC
Annexon reported Q2 2026 results with a net loss of $0.28/share, slightly wider than the prior year's $0.34/share…
8-K — Impact 6/10
Aug 10, 2026 Insider
Blumenkranz Mark S. was granted 175,000 shares
Director
Aug 6, 2026 Press
Annexon announced early positive data from the FORWARD open-label study of tanruprubart in Guillain-Barré syndrome…
Impact 7/10
Jun 30, 2026 Inst.
FMR LLC — ADD
19,518,496 shares ($111.5M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 16, 2026
Earnings date
🔒 Fresh data — subscribers only
Recent
Oct 21, 2026
Clinical Trial
A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy
Phase Phase 2 — COMPLETED
Oct 16, 2026
Press release
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform…
Sep 16, 2026
Press release
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation…
Sep 2, 2026
Press release
Annexon to Participate in Upcoming September Investor Conferences
BRISBANE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation…
Aug 25, 2026
Clinical Trial
An Open Label Study of ANX005 in Participants With, or at Risk for, Manifest Huntington's Disease
Phase Phase 2 — COMPLETED

SecBot reports

11 filings · 2 press releases · 6 bullish · 1 bearish · 1 mixed · 3 neutral
All ANNX filing & press-release reports (13)